News | Breast Density | February 14, 2019

Densitas Enters Partnership Agreement With TeleMammography Specialists

Teleradiology provider will be first U.S. beta user for new densitasquality solution to enhance communication and compliance with FDA EQUIP mammography inspection program

Densitas Enters Partnership Agreement With TeleMammography Specialists

February 14, 2019 — Breast imaging analytics company Densitas Inc. announced a new collaboration partnership with TeleMammography Specialists of Decatur, Ga. TeleMammography Specialists will be the first U.S. beta user for the new densitasquality solution from Densitas, which will be used to improve the communications and information sharing needed to meet EQUIP (Enhancing Quality Using the Inspection Program) guidelines. TeleMammography Specialists will also implement the recently released densitasdensity automated breast density assessment software.

Densitas will highlight the benefits and capabilities of both products at the 2019 Healthcare Information and Management Systems Society (HIMSS) annual meeting, Feb. 11-15 in Orlando, Fla.

TeleMammography Specialists LLC. is an international teleradiology services provider that is specialized in breast imaging. Densitas Quality will help:

  • Streamline efforts to meet the U.S. Food and Drug Administration’s (FDA) EQUIP guidelines and prepare for mammography inspections;
  • Enable real-time feedback from the interpreting physicians to the technologists;
  • Automate EQUIP audit documentation requirements of the lead interpreting physician/auditing physician;
  • Simplify the ability to meet the proactive quality control requirements of EQUIP; and
  • Identify technologist performance issues quickly and accurately to facilitate ongoing training and communication that improves image and service quality.

By making densitasquality and densitasdensity available to all of TeleMammography Specialists clients, over 60,000 women will benefit annually. "Densitas will help us provide consistent quality and standardize density assessment among our radiologists", said Martha H. Garrison, M.D., president and CEO of TeleMammography Specialists, LLC. "We will be able to more proactively manage the needs of our clients and provide consistently high quality of care."

The artificial intelligence (AI)-powered densitasdensity software delivers fully automated, standardized and reliably reproducible breast density assessment. Additionally, densitasdensity results can be incorporated in risk models to generate standardized and reliably reproducible breast cancer risk assessment.

For more information: www.densitas.health

Related Content

For years telehealth has danced at the edges of healthcare
Feature | Teleradiology | January 21, 2021 | By Jef Williams
All indications point to 2021 being the year of the return path of this boomerang event that sent us all in a differe
Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
The key trends Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Imagesbserved at 2020 Radiological Society of North America (RSNA) meeting all focused around COVID-19 (SARS-CoV-2) and the impact it has had on radiology. #RSNA #RSNA20 #RSNA2020

Clinicians reviewing a COVID-19 patient's lung CT that reveals the severity of COVID-caused pneumonia. The impact of COVID on radiology was a major, over arching trend at  the 2020 Radiological Society of North America (RSNA) meeting. Getty Images

Feature | RSNA | January 20, 2021 | By Melinda Taschetta-Millane and Dave Fornell
An interview with Eric Liederman, M.D., MPH, Director of Medical Informatics for The Permanente Medical Group, in Kaiser Permanente’s Northern California Region, on the explosion of telemedicine in the COVID-19 era

Getty Images

Feature | Radiology Business | January 20, 2021 | By Melinda Taschetta-Millane
AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient care, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s flagship image analysis platform.
News | Artificial Intelligence | January 18, 2021
January 18, 2021 — AI Metrics, LLC, a medical imaging startup focused on augmented intelligence to improve patient ca
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...